Physician profile
Lori Gerding
NPI 1801834726
$5,314.95
in general payments reported to CMS, 2019-2025
20 companies · $1,440 in 2025
The $1,440 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $117 · 2021: $682 · 2022: $852 · 2023: $485 · 2024: $1,091 · 2025: $1,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,015.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,316.23 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $1,005.38 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $892.70 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $451.03 | 2024-2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $374.84 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $308.80 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $209.25 | 2021-2025 | Caplyta |
| Lundbeck LLC | $173.92 | 2019-2024 | Rexulti |
| Allergan, INC. | $125.80 | 2019 | |
| Vanda Pharmaceuticals INC. | $101.96 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $81.43 | 2019-2022 | |
| Abbvie INC. | $70.26 | 2022-2024 | |
| Abbott Laboratories | $39.13 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $35.58 | 2025 | Cobenfy |
| Indivior INC. | $33.82 | 2023-2024 | Perseris |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $32.22 | 2024 | |
| Axsome Therapeutics, INC. | $17.81 | 2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $16.64 | 2021 | |
| Eisai INC. | $14.34 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Gerding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.